GLP-2 TRZ (Tirzepatide) is a synthetic research peptide designed as a dual receptor agonist targeting the GLP-1 and GIP receptors.

In preclinical studies and clinical investigations, tirzepatide has been associated with significant reductions in body weight, along with improvements in glycemic control, insulin sensitivity, and lipid metabolism. Research has also explored its potential effects on energy balance, metabolic regulation, and adipose tissue signaling pathways.

This product is supplied strictly for research purposes only and is not intended for human or animal consumption or therapeutic use.